H.C. Wainwright analyst Robert Burns raised the firm’s price target on Aktis Oncology (AKTS) to $33 from $30 and keeps a Buy rating on the shares following the Q4 report. The firm says the company’s pipeline is slated to advance and grow over the next 12 months.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKTS:
- Aktis Oncology announces FDA clearance of AKY-25191 trial
- 3 Best Stocks to Buy Today, 3/9/2026, According to Top Analysts
- Aktis Oncology initiated with a Buy at H.C. Wainwright
- Aktis Oncology’s NECTINIUM-2 Trial: A New Radiopharma Bet in Solid Tumors
- Aktis Oncology: Fast-Track Momentum and Pipeline Catalysts Underpin Buy Rating and $34 Price Target